[go: up one dir, main page]

MA47495A - Compositions anti-inflammatoires comprenant des inhibiteurs d'irak et de jak - Google Patents

Compositions anti-inflammatoires comprenant des inhibiteurs d'irak et de jak

Info

Publication number
MA47495A
MA47495A MA047495A MA47495A MA47495A MA 47495 A MA47495 A MA 47495A MA 047495 A MA047495 A MA 047495A MA 47495 A MA47495 A MA 47495A MA 47495 A MA47495 A MA 47495A
Authority
MA
Morocco
Prior art keywords
iraq
compositions including
jak inhibitors
inflammatory compositions
inflammatory
Prior art date
Application number
MA047495A
Other languages
English (en)
Inventor
David Amantini
Reginald Christophe Xavier Brys
Philippe Clément-Lacroix
Vos Steve Irma Joel De
René Alexandre Galien
Original Assignee
Galapagos Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Galapagos Nv filed Critical Galapagos Nv
Publication of MA47495A publication Critical patent/MA47495A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
MA047495A 2017-02-17 2018-02-15 Compositions anti-inflammatoires comprenant des inhibiteurs d'irak et de jak MA47495A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1702603.0A GB201702603D0 (en) 2017-02-17 2017-02-17 Novel compositions and pharmaceutical compositions thereof for the treatment of inflammatory disorders

Publications (1)

Publication Number Publication Date
MA47495A true MA47495A (fr) 2019-12-25

Family

ID=58486866

Family Applications (1)

Application Number Title Priority Date Filing Date
MA047495A MA47495A (fr) 2017-02-17 2018-02-15 Compositions anti-inflammatoires comprenant des inhibiteurs d'irak et de jak

Country Status (13)

Country Link
EP (1) EP3582775A1 (fr)
JP (1) JP2020507612A (fr)
KR (1) KR20190117672A (fr)
CN (1) CN110300586A (fr)
AU (1) AU2018221761A1 (fr)
BR (1) BR112019016949A2 (fr)
CA (1) CA3054652A1 (fr)
GB (1) GB201702603D0 (fr)
MA (1) MA47495A (fr)
MX (1) MX2019009658A (fr)
PH (1) PH12019501853A1 (fr)
SG (1) SG11201907492TA (fr)
WO (1) WO2018149925A1 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019111218A1 (fr) 2017-12-08 2019-06-13 Cadila Healthcare Limited Nouveaux composés hétérocycliques utilisés en tant qu'inhibiteurs d'irak4
CN113713083A (zh) * 2020-05-25 2021-11-30 南京帝昌医药科技有限公司 一种用于治疗脱发的药物组合
CN115843296B (zh) * 2020-08-07 2024-03-08 南京迈晟科技有限责任公司 Cdk9抑制剂及其用途

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3041B1 (ar) 2008-07-25 2016-09-05 Galapagos Nv مركبات جديدة مفيدة لمعالجة الأمراض التنكسية والالتهابية
TWI462920B (zh) 2009-06-26 2014-12-01 葛萊伯格有限公司 用於治療退化性及發炎疾病之新穎化合物
EP2863950B1 (fr) 2012-06-22 2018-07-18 Galapagos NV Aminotriazolopyridine pour l'utilisation dans le traitement de l'inflammation, et compositions pharmaceutiques associées
GB201402070D0 (en) 2014-02-07 2014-03-26 Galapagos Nv Pharmaceutical compositions for the treatment of inflammatory disorders
GB201402071D0 (en) 2014-02-07 2014-03-26 Galapagos Nv Novel salts and pharmaceutical compositions thereof for the treatment of inflammatory disorders
GB201518456D0 (en) * 2015-10-19 2015-12-02 Galapagos Nv Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory, autoimmune and/or proliferative diseases
US20170173034A1 (en) * 2015-12-17 2017-06-22 Gilead Sciences, Inc. Combination of a jak inhibitor and a syk inhibitor for treating cancers and inflammatory disorders

Also Published As

Publication number Publication date
WO2018149925A1 (fr) 2018-08-23
AU2018221761A1 (en) 2019-10-03
PH12019501853A1 (en) 2020-06-15
CN110300586A (zh) 2019-10-01
SG11201907492TA (en) 2019-09-27
BR112019016949A2 (pt) 2020-05-26
JP2020507612A (ja) 2020-03-12
KR20190117672A (ko) 2019-10-16
EP3582775A1 (fr) 2019-12-25
GB201702603D0 (en) 2017-04-05
MX2019009658A (es) 2019-10-02
CA3054652A1 (fr) 2018-08-23

Similar Documents

Publication Publication Date Title
EP3607044C0 (fr) Compositions détergentes et leurs utilisations
EP3673055A4 (fr) Méthodes et compositions de ciblage d'arn
EP3746071A4 (fr) Inhibiteurs de gcn2 et leurs utilisations
EP3860449A4 (fr) Agencement d'électrodes
EP3746075A4 (fr) Inhibiteurs de gcn2 et leurs utilisations
MA46427A (fr) Compositions d'oligonucléotides et procédés associés
EP3419676A4 (fr) Compositions antimicrobiennes et leurs utilisations
MA45270A (fr) Compositions d'oligonucléotides et procédés associés
EP3712997A4 (fr) Ensemble d'électrodes
EP3566085A4 (fr) Ensemble d'affichage
EP3893945A4 (fr) Esters cromoglycique et leurs utilisations
EP3924323A4 (fr) Compositions de tricyclodécane diméthanol et leurs utilisations
EP3380471A4 (fr) Méthodes et compositions d'inhibition de comt
EP3813856A4 (fr) Compositions de cellules et leurs utilisations
EP3695216A4 (fr) Électrode d'étalonnage
EP3641847A4 (fr) Robinet d'arrêt
EP3651748A4 (fr) Compositions antimicrobiennes efficaces contre les bactéries et les champignons
MA47203A (fr) Inhibiteurs d'antiport à médiation par nhe
EP3598556A4 (fr) Électrode et ensemble d'électrodes
EP3768272A4 (fr) Inhibiteurs de jak
EP3592377A4 (fr) Formes posologiques de kallicréine tissulaire 1
MA53648A (fr) Inhibiteurs d'o-glycoprotéine-2-acétamido-2-désoxy-3-d-glucopyranosidase
EP3491329A4 (fr) Propergol et compositions d'auto-protection
EP3683880A4 (fr) Ensemble d'électrodes
EP3775261A4 (fr) Compositions de fraction de liaison cible et procédés d'utilisation